Citadel Advisors
XFOR icon

Citadel Advisors’s X4 Pharmaceuticals XFOR Stock Holding History

Citadel Advisors’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-128,675
Closed -$515K – 14383
2025
Q4 		$515K Buy
+128,675
New +$467K ﹤0.01% 8960
2024
Q3 		– Sell
-280
Closed -$5.84K – 15383
2024
Q2 		$4.88K Sell
280
-25,148
-99% -$822K ﹤0.01% 13449
2024
Q1 		$1.06M Sell
25,428
-32,174
-56% -$895K ﹤0.01% 6799
2023
Q4 		$1.45M Sell
57,602
-2,352
-4% -$57.2K ﹤0.01% 5956
2023
Q3 		$1.96M Sell
59,954
-42,503
-41% -$1.85M ﹤0.01% 5251
2023
Q2 		$5.96M Buy
102,457
+101,858
+17,005% +$5.23M ﹤0.01% 3373
2023
Q1 		$15.6K Sell
599
-30,896
-98% -$906K ﹤0.01% 13246
2022
Q4 		$938K Buy
+31,495
New +$1.49M ﹤0.01% 6940
2022
Q3 		– Sell
-1,508
Closed -$52.1K – 13738
2022
Q2 		$44K Sell
1,508
-342
-18% -$13K ﹤0.01% 12015
2022
Q1 		$97K Sell
1,850
-740
-29% -$42.4K ﹤0.01% 12315
2021
Q4 		$178K Buy
2,590
+1,459
+129% +$185K ﹤0.01% 12026
2021
Q3 		$180K Sell
1,131
-438
-28% -$72.1K ﹤0.01% 12132
2021
Q2 		$306K Buy
+1,569
New +$394K ﹤0.01% 11212
2020
Q2 		– Sell
-387
Closed -$116K – 10612
2020
Q1 		$116K Buy
+387
New +$110K ﹤0.01% 8529

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Citadel Advisors's XFOR Position: Q1 2026 in Review

Citadel Advisors sold out of X4 Pharmaceuticals (XFOR) in Q1 2026, closing a stake of 128,675 shares — an estimated $515K sold.

Citadel Advisors first reported a position in XFOR in Q1 2020 and held it in 14 quarters. The position peaked at $5.96M in Q2 2023. 84 funds tracked by Wall St. Rank hold XFOR as of Q1 2026.

  • Citadel Advisors reported no remaining X4 Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 128,675 X4 Pharmaceuticals shares in Q1 2026, an estimated $515K.
  • Citadel Advisors first reported a position in X4 Pharmaceuticals in Q1 2020 and held it in 14 quarters.
  • Citadel Advisors's X4 Pharmaceuticals position peaked at $5.96M in Q2 2023.
  • 84 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.